Trial Profile
A Phase 1, Multi-Center, Placebo-Controlled, Dose-Escalation Study of the Safety of IMO-2125 in Hepatitis C-Infected Patients Unresponsive to Standard Treatment With Pegylated Interferon and Ribavirin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs Tilsotolimod (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; First in man
- 11 Mar 2011 Status changed from active, no longer recruiting to completed based on information reported in an Idera Pharmaceuticals media release.
- 01 Nov 2010 Status changed from recruiting to active, no longer recruiting.
- 31 Oct 2010 Results have been presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), according to an Idera Pharmaceuticals media release.